LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

First-Ever SARS-CoV-2 Antibody Test Indicates Whether Patients Require COVID-19 Booster

By LabMedica International staff writers
Posted on 23 Jun 2022
Print article
Image: PictArray SARS-CoV-2 Antibody Test has received CE Mark (Photo courtesy of Pictor)
Image: PictArray SARS-CoV-2 Antibody Test has received CE Mark (Photo courtesy of Pictor)

The COVID-19 pandemic remains a healthcare concern as new strains of the virus have emerged. Now, a first-of-its-kind test enables personalized COVID-19 assessments by detecting if a patient has antibodies from a previous infection of SARS-CoV-2 or from vaccination alone.

The PictArray SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) antibody test from Pictor Limited (Auckland, New Zealand) detects if a person has antibodies from a previous SARS-CoV-2 infection (from spike protein (SP) and nucleocapsid protein (NP) antibodies) or from COVID-19 vaccination alone (SP antibodies only). The test also indicates whether at-risk patients have failed to mount a detectable antibody response despite vaccination or infection (SP and NP negative).

Pictor has received confirmation of CE registration for its PictArray SARS-CoV-2 IgG ELISA antibody test as per In Vitro Diagnostic Directive (IVDD) regulations, allowing it to market the COVID-19 antibody test in Europe and gain regulatory approval in Southeast Asia.

“Receiving CE registration enables Pictor to establish a footprint with partner laboratories and research bodies within Europe which is an important market for us,” said Howard Moore, CEO of Pictor. “Our recent successful funding round means we are well equipped to support market development and launches within the European Economic Area while continuing existing work across ANZ, the U.S., India and Southeast Asia.”

“As we learn more about COVID-19, the separate detection of SP and NP will enable a more precise assessment of a patient’s immunity against SARS-CoV-2 and help guide any associated clinical interventions whilst also informing wider public health measures when mass serosurveys are conducted,” added Pictor’s Chief Medical Officer Tadd Lazarus, MD.

Related Links:
Pictor Limited 

Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.